The Michigan Institute for Clinical & Health Research (MICHR) at the University of Michigan has selected the OpenClinica Enterprise clinical trial software platform to support a growing clinical study portfolio. Starting this fall, MICHR will begin deployment of OpenClinica for a wide variety of clinical trials.
According to Jim Maszatics, Clinical Research Informatics Core (CRIC) Manager at MICHR, OpenClinica offers a robust infrastructure that will enhance MICHR’s competitiveness for extramural funding. “Static budgets and budget cuts from the NIH are causing government-sponsored grants to become more competitive than ever. With OpenClinica, we are able to put in place an enterprise-quality, regulatory compliant electronic data capture and clinical data management system that will make us more attractive to both government-sponsored and industry-sponsored clinical trials.”
In addition to its regulatory compliance capabilities, MICHR cited OpenClinica’s flexibility to support a wide variety of studies off the same platform, thereby increasing the institute’s efficiency. This efficiency will serve MICHR well in its support of a large and growing number of diverse clinical studies.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.